Please login to the form below

Not currently logged in

EPEMED appoints Emmanuelle Benzimra as general delegate

Three board members also appointed including Janssen’s Wenrer Verbiest and GSK’s Peter Collins

Emmanuelle Benzimra - EPEMEDThe European Personalised Medicine association (EPEMED) has named Emmanuelle Benzimra as its general delegate, as well as three new additions to its board.

According to the not-for-profit, which aims to bring together companies and organisations involved in the progression of personalised medicine, Benzimra has experience in both the financial and investment banking industries as well as in supporting non-profit start-ups.

She is also currently in the middle of founding Bench2Cures, which aims to fund and accelerate the journey of products from laboratories to use in patients.

In addition to Benzimra's appointment, EPEMED added three new members to its board: Werner Verbiest, global head of Janssen Diagnostics; Peter Collins, head of diagnostics at GlaxoSmithKline (GSK); and Patrizia Luchetta, director of new technologies at the Ministry of the Economy and of Foreign Trade, Grand Duchy of Luxembourg.

Verbiest has played a leading role in progressing a personalised approach to medicine within Johnson & Johnson and Janssen, a company he originally joined in 1991. He has experience in the development of HIV drugs and hepatitis B vaccines.

Collins currently leads GSK's efforts to support the diagnostic needs of GSK's clinical development programmes across all business units.

He has over 30 years experience in the diagnostics industry, specialising in personalised medicines and companion diagnostics. His previous roles prior to joining GSK include VP pharma business development for Qiagen.

Patrizia Luchetta has been with the Ministry of Economy since 2006, helping to develop Luxembourg's health sciences and technologies hub and expand research opportunities in the country.

Benzimra said: “I am impressed by the dynamic that EPEMED created in such a short period and the body of leading experts it did attract.

“EPEMED is now in a pivotal position to represent a notorious centre of influence towards European institutions and governments for the mass introduction of personalised medicine in healthcare systems and harmonisation of practices for the benefit of patients.”

15th June 2012


Featured jobs

Subscribe to our email news alerts


Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...